

Hormone therapy not beneficial in subclinical hypothyroidism

15 October 2018



"These findings do not support the routine use of thyroid hormone <u>therapy</u> in <u>adults</u> with subclinical hypothyroidism," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

More information: <u>Abstract/Full Text</u> (subscription or payment may be required)

Copyright © 2018 HealthDay. All rights reserved.

(HealthDay)—Thyroid hormone therapy is not associated with improvements in general quality of life or thyroid-related symptoms in non-pregnant adults with subclinical hypothyroidism, according to a review published in the Oct. 2 issue of the *Journal of the American Medical Association*.

Martin Feller, M.D., from the University of Bern in Switzerland, and colleagues conducted a systematic literature review to identify randomized clinical trials that compared thyroid <u>hormone</u> therapy to placebo or no therapy in non-pregnant adults with subclinical hypothyroidism. Their analysis included 21 studies with 2,192 adults.

The researchers found that after treatment (range, three to 18 months), thyroid hormone therapy was associated with a reduction in the mean thyrotropin value to the normal reference range versus placebo, but it was not associated with benefit regarding general quality of life or thyroid-related symptoms. Included studies had a low risk of bias and moderate- to high-quality evidence.



APA citation: Hormone therapy not beneficial in subclinical hypothyroidism (2018, October 15) retrieved 29 April 2021 from <u>https://medicalxpress.com/news/2018-10-hormone-therapy-beneficial-subclinical-hypothyroidism.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.